| Title (priority date): |
| Reference: |
045 |
| Inventors: |
Cornils, Dirnhofer & Hemmings |
| Description: |
The inventors observed that lymphoma development due to abherant NDR1 and/or NDR2 expression is late onset. This suggest that early detection of abherant NDR1 and/or NDR2 expression may allow for treatmetn before disease ocurs. |
| Applications: |
Cancer therapy, screening for anti-cancer agents |
| Status: |
PCT pending |
| Opportunity: |
Exclusive or non-exclusive licenses |
| Publications: |
|
| Contact: |
Dr. Nicolas Favre, tel: +41 61 6978382, e-mail: nicolas.favre@fmi.ch |
| PCT File: |
WO2008/065391 |
